We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

By LabMedica International staff writers
Posted on 21 Oct 2026

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. More...

These tasks can be time-consuming and vary between readers, while insufficient tumor content can cause molecular tests to fail. To streamline these assessments, a newly launched artificial intelligence product family analyzes hematoxylin and eosin (H&E) whole-slide images, helping laboratories prioritize cases and evaluate sample suitability before molecular testing.

Aignostics (Berlin, Germany) has launched HETA Clinical, a pan-cancer family of artificial intelligence (AI) products designed to support pathology workflows from intake and evaluation through preparation for molecular testing. The initial portfolio includes HETA Quality Control, HETA Tumor Detect, HETA Mitosis, and HETA Tumor Cellularity. Together, these tools assess slide quality, tumor presence, mitotic counts, and tumor cellularity across hematoxylin and eosin (H&E) whole-slide images.

HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. These flags can help prioritize cases for review and support ordering additional stains at intake. HETA Mitosis provides a reproducible mitotic count, and HETA Tumor Cellularity measures tumor cell content and proposes a region containing sufficient tumor for molecular testing.

All four products build on HETA, formerly Atlas H&E-TME, Aignostics’ core pan-cancer platform for spatial H&E tissue analysis. In a recent study cited by the company, HETA’s cell classification performance matched or exceeded that of expert pathologists. The focus on tumor cellularity also addresses a practical laboratory challenge: pathologists at leading academic medical centers and precision medicine laboratories estimated that 10% to 20% of molecular tests fail because tissue contains insufficient tumor, potentially requiring repeat biopsies and causing lengthy delays.

The products are for research use only and are not for use in diagnostic procedures. Aignostics plans to expand the HETA Clinical product family over time and integrate the products with image management systems, including Techcyte Fusion AP.

“HETA Clinical gives labs a faster path through their workflow. Measurements like tumor content and mitotic count are central to many pathology specialties and shape much of the work that follows a slide. Quantifying them cell by cell is where AI delivers consistency at scale, freeing pathologists' time for the parts of the work that need their expertise,” said Dr. Rosemarie Krupar, VP of Pathology at Aignostics.

Related Links
Aignostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.